GOSS Gossamer Bio, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Gossamer Bio, Inc. (GOSS) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 17, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on April 9, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Gossamer Bio, Inc. (GOSS) (SEC CIK 1728117), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year FY2025 financial results reported March 17, 2026
- • Full results in Exhibit 99.1 press release — primary source for revenue, cash, and pipeline spend figures
Item 8.01: Other Events
- • Phase 3 PROSERA missed primary endpoint: p=0.0320 failed prespecified α=0.025 threshold; seralutinib showed +13.3m 6MWD improvement vs placebo but statistical bar not cleared
- • Strong signal in intermediate/high-risk subgroup (n=234, ~60% of trial): +20.0m placebo-adjusted 6MWD gain (p=0.0207); 3 of 4 key secondaries below p=0.0125
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Gossamer Bio, Inc. (GOSS) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 9, 2026 | — | — | — |
8-K | Mar 17, 2026 | — | Analysis | — |
10-K | Mar 17, 2026 | Dec 31, 2025 | — | |
8-K | Feb 23, 2026 | — | Analysis | — |
10-Q | Nov 5, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 5, 2025 | Jun 30, 2025 | — | |
10-Q | May 15, 2025 | Mar 31, 2025 | — | |
10-K | Mar 13, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 12, 2024 | Jun 30, 2024 | — | |
10-Q | May 7, 2024 | Mar 31, 2024 | — | |
10-K | Mar 5, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 8, 2023 | Jun 30, 2023 | — | |
10-Q | May 9, 2023 | Mar 31, 2023 | — | |
10-K | Mar 17, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 9, 2022 | Jun 30, 2022 | — | |
10-Q | May 10, 2022 | Mar 31, 2022 | — | |
10-K | Mar 3, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 8, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 9, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — | |
10-K | Feb 26, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 10, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest GOSS SEC filings in 2026?
Gossamer Bio, Inc. (GOSS) has filed a 10-K annual report on March 17, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on April 9, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did GOSS file its most recent 10-K annual report?
Gossamer Bio, Inc. (GOSS) filed its most recent 10-K annual report on March 17, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view GOSS 10-Q quarterly reports?
Gossamer Bio, Inc. (GOSS)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every GOSS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has GOSS filed recently?
Gossamer Bio, Inc. (GOSS)'s most recent 8-K was filed on April 9, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find GOSS insider trading activity (Form 4)?
SignalX aggregates every GOSS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does GOSS file with the SEC?
Gossamer Bio, Inc. (GOSS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new GOSS filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Gossamer Bio, Inc. (GOSS).
What is GOSS's SEC CIK number?
Gossamer Bio, Inc. (GOSS)'s SEC CIK (Central Index Key) number is 1728117. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1728117 to look up all GOSS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find GOSS return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Gossamer Bio, Inc. (GOSS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Gossamer Bio, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 32+ filings.